DPDoctor's PassportEducation
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
RapidMLAMSRAFoundation

Palliative radiotherapy and symptom control

Essential points for quick revision.

!
Neurological, airway or haemorrhagic compromise before radiotherapy

New weakness or sphincter dysfunction, impending brain herniation, stridor, major haemorrhage, unstable fracture or obstructed viscus requires immediate physiological and anatomical rescue; radiotherapy may contribute but is not a substitute for stabilisation.

Action: Use ABCDE care, control bleeding and protect an unstable spine or limb. Give dexamethasone 16 mg for neurological metastatic cord compression, obtain whole-spine MRI within 24 hours and seek urgent surgical and radiation review; use airway, neurosurgical, endoscopic, embolisation or operative intervention first when delay for radiation would risk irreversible harm.

Synopsis

Select palliative radiotherapy for a defined pain, bleeding, compression or neurological target, stabilise emergencies before planning, choose the shortest evidence-based fractionation that meets the goal and anticipate response, flare, field toxicity, retreatment and supportive care.

  • Palliative radiotherapy is local treatment for a defined symptom or threatened structure; it does not treat every site of metastatic disease simultaneously.
  • Common indications include uncomplicated painful bone metastasis, selected MSCC, brain metastasis, tumour bleeding, painful soft-tissue mass, airway or venous compression and skin ulceration.
  • First-line assessment defines the exact symptom, anatomical target, emergency, expected survival, performance, previous radiation, systemic options, travel burden and patient goal.

Key red flags

Back pain with weakness, gait change, sensory loss or bladder or bowel dysfunction requires the MSCC emergency pathway before a routine radiotherapy referral.

Neurological emergency

Weakness, sensory or sphincter change, falling consciousness or posterior-fossa pressure needs urgent imaging, steroid when indicated and decompression assessment.

Investigation priorities

01
First-line symptom, function and goal assessmentFirst stepFirst line

Define the target, mechanism, severity, emergency, performance, prognosis, previous local treatment and outcome the patient values.

Management branches

Urgent referralStabilise first and select the fastest effective sequence

Tumour causes neurological loss, airway compromise, unstable bone, major bleeding or obstructed organ.

  1. Use ABCDE care and activate MSCC, intracranial, airway, haemorrhage or fracture pathway with corticosteroid, transfusion, immobilisation or decompression as indicated.
  2. Obtain the time-critical imaging and joint surgical, interventional and radiation review, deciding whether an operation, embolisation, stent or drain must precede radiation.

Key medicines

Dexamethasone for neurological MSCCGive dexamethasone 16 mg orally immediately, or equivalent parenterally, when neurological symptoms or signs suggest MSCC, then 16 mg daily while surgery or radiotherapy is awaited and taper after definitive treatment starts.
Analgesic cover for radiation response and flareContinue the established regular non-opioid and opioid schedule with immediate-release rescue matched to current 24-hour exposure; some services use a short dexamethasone course for high bone-pain-flare risk.
Open full textbook Answer 2 questions
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom